Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Better TAVR Outcomes With More Experienced Operators: New York Database

Michael O'Riordan

December 12, 2018

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

News Daily News

FORWARD Registry: Low Mortality Rate Seen 1 Year After TAVR With Evolut R

Todd Neale

November 20, 2018

News Daily News

Isolated SAVR Volumes Slide as TAVR Numbers Mount in the US

Yael L. Maxwell

October 19, 2018

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

News Daily News

Early Discharge Safe in Patients Undergoing TAVR, Meta-analysis Shows

Michael O'Riordan

September 12, 2018

News Daily News

Late Conduction Defects After TAVR: Finding ‘Sweet Spot’ for Early Discharge

Michael O'Riordan

August 08, 2018

News Daily News

Hemodynamic Deterioration Post-SAVR: Dysmetabolic Profile, Calcification Could Be Early Warning Signs

Caitlin E. Cox

July 10, 2018

News Daily News

Valve-in-Valve TAVR: Mortality, Adverse Events Similar to Redo Surgery at 30 Days

Yael L. Maxwell

April 25, 2018

News Daily News

‘Striking’ Rise in TAVR Among Patients With Previous CABG

Shelley Wood

April 13, 2018

News Daily News

Delayed Coronary Obstruction After TAVR: Prevalence, Causes, and Solution Explored for Deadly Complication

Yael L. Maxwell

April 02, 2018

News Daily News

Coronary Procedures After TAVR: New Practical Guide Reviews Tools, Techniques

Yael L. Maxwell

March 23, 2018

News Daily News

Meta-analysis Raises ‘Red Flag’ on TAVR in Low-Risk Patients

L.A. McKeown

February 07, 2018

News Daily News

Structural Valve Degeneration: VIVID Group Proposes New, Graduated Definition

Michael O'Riordan

January 26, 2018

News Daily News

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

Shelley Wood

January 05, 2018

Advertisement

Better TAVR Outcomes With More Experienced Operators: New York Database

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

FORWARD Registry: Low Mortality Rate Seen 1 Year After TAVR With Evolut R

Isolated SAVR Volumes Slide as TAVR Numbers Mount in the US

High Mortality but Durable Results With Valve-in-Valve TAVR

Early Discharge Safe in Patients Undergoing TAVR, Meta-analysis Shows

Late Conduction Defects After TAVR: Finding ‘Sweet Spot’ for Early Discharge

Hemodynamic Deterioration Post-SAVR: Dysmetabolic Profile, Calcification Could Be Early Warning Signs

Valve-in-Valve TAVR: Mortality, Adverse Events Similar to Redo Surgery at 30 Days

‘Striking’ Rise in TAVR Among Patients With Previous CABG

Delayed Coronary Obstruction After TAVR: Prevalence, Causes, and Solution Explored for Deadly Complication

Coronary Procedures After TAVR: New Practical Guide Reviews Tools, Techniques

Meta-analysis Raises ‘Red Flag’ on TAVR in Low-Risk Patients

Structural Valve Degeneration: VIVID Group Proposes New, Graduated Definition

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content